<?xml version="1.0" encoding="UTF-8"?>
<p>The EBOVAC-Salone study is assessing the safety and immunogenicity of the Ad26.ZEBOV/MVA-BN-Filo prime-boost regimen in a population affected by Ebola and is being carried out in Kambia District in northern Sierra Leone. It is coordinated by the London School of Hygiene &amp; Tropical Medicine, in collaboration with the College of Medicine and Allied Health Sciences in Sierra Leone, and is sponsored by Janssen. The Innovative Medicines Initiative is also funding the related Ebola Vaccine Deployment, Acceptance and Compliance consortium which supports communications, community engagement and enabling technologies for the EBOVAC-Salone trial.
 <sup>
  <xref rid="bibr4-1740774518780678" ref-type="bibr">4</xref>
 </sup>
</p>
